Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardio-vascular Disease
Response to Cicero et al.
- Edith D. Beishuizen, MD1,
- Marcel A. van de Ree, MD, PHD2,
- J. Wouter Jukema, MD, PHD3,
- Jouke T. Tamsma, MD, PHD1 and
- Menno V. Huisman, MD, PHD1
- 1Department of General Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
- 2Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands
- 3Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
- Address correspondence to E.D. Beishuizen, Department of General Internal Medicine, C1-R41, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, Netherlands. E-mail: e.d.beishuizen{at}lumc.nl
We thank Cicero et al. (1) for their comments on our article (2). We measured intima-media thickness (IMT) at baseline and after 1 and 2 years. Thus, the assertion by Cicero et al. that we “should have concluded that 15.4 months of treatment with 0.4 mg cerivastatin…is not efficacious in reducing IMT progression in type 2 diabetic subjects” cannot, in our view, be drawn from the data as gathered. Although the level of LDL cholesterol was significantly higher during 20-mg simvastatin treatment compared with 0.4-mg cerivastatin treatment (2.56 …
